Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients
Information source: University Hospital Inselspital, Berne
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: End Stage Renal Disease
Intervention: oral 18B Glycyrrhetinic acid versus placebo (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: University Hospital Inselspital, Berne Official(s) and/or principal investigator(s):
Felix J Frey, Prof, Principal Investigator, Affiliation: Department of Nephrology and Hypertension, University hospital of Berne
Overall contact:
Stefan Farese, MD, Phone: + 41 31 632 31 44, Email: stefan.farese@insel.ch
Summary
Background: 18B Glycyrrhetinic acid (active compound of Licorice) decreases serum potassium
via enhanced renal potassium loss in healthy individuals and thereby inducing renal sodium
retention and arterial hypertension. In dialysis patients this mechanism is disturbed and
compensatory intestinal potassium secretion is enhanced. 18B Glycyrrhetinic acid is an
inhibitor of 11B Hydroxysteroid dehydrogenase type 1 (11b HSD1). Inhibition of 11 b HSD1
offers a novel potential therapy to lower intracellular cortisol concentrations and thereby
enhance insulin sensitivity.
Hypothesis: Glycyrrhetinic acid decreases serum potassium by enhanced intestinal excretion
in dialysis patients and increases insulin sensivity by inhibition of 11b HSD
Methods: double blind, 6 month cross over trial comparing oral 18b Glycyrrhetinic acid with
placebo in 24 nondiabetic dialysis patients.
Endpoints: predialytic serum potassium levels, insuline sensitivity assessed by fasting
glucose and fasting insulin concentrations
Clinical Details
Official title: Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- dialysis patients (>3 months)
Exclusion Criteria:
- diabetics
- hospital stay in the last 4 weeks
Locations and Contacts
Stefan Farese, MD, Phone: + 41 31 632 31 44, Email: stefan.farese@insel.ch
Department of nephrology and hypertension, University hospital of berne, Berne 3010, Switzerland; Recruiting
Stefan Farese, MD, Phone: +41 31 631 31 44, Email: stefan.farese@insel.ch
Felix J Frey, Prof, Principal Investigator
Additional Information
Starting date: August 2006
Ending date: August 2007
Last updated: October 5, 2006
|
